GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Upstream Bio Inc (NAS:UPB) » Definitions » Total Stockholders Equity

UPB (Upstream Bio) Total Stockholders Equity : $445.61 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Upstream Bio Total Stockholders Equity?

Upstream Bio's Total Stockholders Equity for the quarter that ended in Mar. 2025 was $445.61 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Upstream Bio's Book Value per Share for the quarter that ended in Mar. 2025 was $8.31. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Upstream Bio's Debt-to-Equity for the quarter that ended in Mar. 2025 was 0.00.

Upstream Bio Total Stockholders Equity Historical Data

The historical data trend for Upstream Bio's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Upstream Bio Total Stockholders Equity Chart

Upstream Bio Annual Data
Trend Dec22 Dec23 Dec24
Total Stockholders Equity
-106.16 -123.13 469.85

Upstream Bio Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Stockholders Equity Get a 7-Day Free Trial - -146.61 -160.31 469.85 445.61

Upstream Bio  (NAS:UPB) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Upstream Bio's Book Value per Share for the quarter that ended in Mar. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(445.61-0)/53.641
=8.31

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Upstream Bio's Debt-to-Equity for the quarter that ended in Mar. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.708 + 0.992) / 445.61
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Upstream Bio Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Upstream Bio's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Upstream Bio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Upstream Bio Inc (NAS:UPB) » Definitions » Total Stockholders Equity
Comparable Companies
URGN DNA NWBO RGNX PGEN EYPT TRML MNMD CGEM OMER VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
890 Winter Street, Suite 200, Waltham, MA, USA, 02451
Website
https://www.upstreambio.com
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.